{"id":"comparator-atorvastatin","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver transaminases"},{"rate":"2-5","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the mevalonate pathway responsible for de novo cholesterol synthesis in the liver. By reducing intracellular cholesterol levels, the drug upregulates LDL receptors on hepatocytes, increasing clearance of LDL cholesterol from the bloodstream. This leads to significant reductions in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:47.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of risk of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT00541697","phase":"PHASE3","title":"Eze/Simva Switch Study in Diabetics (0653A-807)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-19","conditions":"Diabetes Mellitus, Type 2","enrollment":648},{"nctId":"NCT00092638","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":450},{"nctId":"NCT00092625","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":442},{"nctId":"NCT00092716","phase":"PHASE3","title":"Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-05","conditions":"Hypercholesterolemia","enrollment":655},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00110435","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":1229},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00090168","phase":"PHASE3","title":"Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01-27","conditions":"Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease","enrollment":435},{"nctId":"NCT00395603","phase":"PHASE3","title":"Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Cardiovascular Diseases, Diabetes Mellitus","enrollment":550},{"nctId":"NCT00442897","phase":"PHASE4","title":"Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Hypercholesterolemia","enrollment":229},{"nctId":"NCT00496730","phase":"PHASE3","title":"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":256},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT02550288","phase":"PHASE3","title":"A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2015-09-29","conditions":"Hypercholesterolemia","enrollment":309},{"nctId":"NCT00462748","phase":"PHASE3","title":"A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Hypercholesterolemia","enrollment":786},{"nctId":"NCT03768427","phase":"PHASE3","title":"Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-27","conditions":"Hypercholesterolemia","enrollment":454},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT00092690","phase":"PHASE3","title":"MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-06","conditions":"Hypercholesterolemia","enrollment":1902},{"nctId":"NCT03273972","phase":"NA","title":"INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-09-07","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":30},{"nctId":"NCT03837925","phase":"PHASE3","title":"Pharmaco-metabolomic Effects of Statins: METASTATINE","status":"COMPLETED","sponsor":"French Cardiology Society","startDate":"2019-06-13","conditions":"Cardiovascular Diseases","enrollment":120},{"nctId":"NCT04631536","phase":"PHASE3","title":"Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC","status":"UNKNOWN","sponsor":"Lebanese American University Medical Center","startDate":"2021-01-10","conditions":"Covid19","enrollment":42},{"nctId":"NCT01154036","phase":"PHASE3","title":"MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-07","conditions":"Hypercholesterolemia","enrollment":1547},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT01859455","phase":"PHASE1","title":"Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Hypercholesterolemia, LDL Cholesterol","enrollment":25},{"nctId":"NCT04511000","phase":"PHASE4","title":"Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-10-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT03507374","phase":"EARLY_PHASE1","title":"PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis","status":"TERMINATED","sponsor":"University of Utah","startDate":"2018-10-30","conditions":"Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage","enrollment":20},{"nctId":"NCT03338426","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-01-15","conditions":"Essential Hypertension, Dyslipidemia","enrollment":133},{"nctId":"NCT00690443","phase":"PHASE2","title":"Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2008-05","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT03346187","phase":"PHASE1","title":"A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-05-19","conditions":"Dyslipidemias","enrollment":60},{"nctId":"NCT00701883","phase":"PHASE2","title":"Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-08","conditions":"Hyperlipidemia","enrollment":183},{"nctId":"NCT00990808","phase":"PHASE1","title":"The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Dyslipidemia","enrollment":46},{"nctId":"NCT01766076","phase":"PHASE3","title":"Atorvastatin for HAART Suboptimal Responders","status":"COMPLETED","sponsor":"Makerere University","startDate":"2013-01","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":30},{"nctId":"NCT00977288","phase":"PHASE2","title":"A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Dyslipidemia","enrollment":408},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT01279590","phase":"PHASE2","title":"Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)","status":"COMPLETED","sponsor":"Furiex Pharmaceuticals, Inc","startDate":"2011-03","conditions":"Myalgia, Hypercholesterolemia, Hyperlipidemia","enrollment":282},{"nctId":"NCT00664469","phase":"PHASE3","title":"INdians Followed for INtensive Lipid Lowering Treatment and Its safetY","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2007-08","conditions":"Hypercholesterolemia","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4666,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lipitor®","atorvastatin","Lipitor ®"],"phase":"marketed","status":"active","brandName":"Comparator: atorvastatin","genericName":"Comparator: atorvastatin","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}